Published in J Med Chem on January 27, 2005
4-chloroprolines: synthesis, conformational analysis, and effect on the collagen triple helix. Biopolymers (2008) 1.13
Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasion. Br J Cancer (2008) 0.88
Modulating collagen triple-helix stability with 4-chloro, 4-fluoro, and 4-methylprolines. Adv Exp Med Biol (2009) 0.86
Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor. BMC Cancer (2008) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase. Nature (2004) 1.86
The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse. Am J Obstet Gynecol (2005) 1.43
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res (2010) 1.38
Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation (2004) 1.31
Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J Am Chem Soc (2005) 1.17
Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain structures. J Pharmacol Exp Ther (2006) 1.16
Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain-derived endothelial cells. Biochem J (2012) 1.15
Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond) (2013) 1.11
Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol (2011) 1.08
Harmonic nanocrystals for biolabeling: a survey of optical properties and biocompatibility. ACS Nano (2012) 1.04
Toxicity screenings of nanomaterials: challenges due to interference with assay processes and components of classic in vitro tests. Nanotoxicology (2015) 0.99
Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin. ChemMedChem (2009) 0.96
Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem (2010) 0.93
Microglial reaction induced by noncytotoxic methylmercury treatment leads to neuroprotection via interactions with astrocytes and IL-6 release. Glia (2002) 0.91
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J Med Chem (2007) 0.90
Evaluation of uptake and transport of ultrasmall superparamagnetic iron oxide nanoparticles by human brain-derived endothelial cells. Nanomedicine (Lond) (2012) 0.89
Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med (Maywood) (2006) 0.89
Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake. J Med Chem (2005) 0.89
Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. J Med Chem (2012) 0.87
Rational design of an organometallic glutathione transferase inhibitor. Angew Chem Int Ed Engl (2009) 0.86
Ruthenium porphyrin compounds for photodynamic therapy of cancer. J Med Chem (2008) 0.86
Discovery of tetrahydro-cyclopenta[b]indole as selective LXRs modulator. Bioorg Med Chem Lett (2009) 0.86
Novel orally active, dibenzazepinone-based gamma-secretase inhibitors. Bioorg Med Chem Lett (2007) 0.86
Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds. Inorg Chem (2012) 0.85
Functionalized pyrrolidine inhibitors of human type II alpha-mannosidases as anti-cancer agents: optimizing the fit to the active site. Bioorg Med Chem (2008) 0.85
A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content. Arterioscler Thromb Vasc Biol (2005) 0.85
SEAP expression in transiently transfected mammalian cells grown in serum-free suspension culture. Cytotechnology (2003) 0.84
Thermoresponsive chlorambucil derivatives for tumour targeting. Angew Chem Int Ed Engl (2011) 0.84
Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase. J Med Chem (2003) 0.83
Molecular imaging by micro-CT: specific E-selectin imaging. Eur Radiol (2009) 0.83
Synthesis of chemically functionalized superparamagnetic nanoparticles as delivery vectors for chemotherapeutic drugs. Bioorg Med Chem (2007) 0.83
Glycosylation pathways as drug targets for cancer: glycosidase inhibitors. Mini Rev Med Chem (2006) 0.82
Evaluation of uptake and transport of cationic and anionic ultrasmall iron oxide nanoparticles by human colon cells. Int J Nanomedicine (2012) 0.82
Studies toward new anti-cancer strategies based on alpha-mannosidase inhibition. Chimia (Aarau) (2010) 0.82
Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin. Inorg Chem (2007) 0.81
Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors. J Med Chem (2009) 0.81
In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. Chemistry (2008) 0.81
Organometallic cages as vehicles for intracellular release of photosensitizers. J Am Chem Soc (2011) 0.81
Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs. ChemMedChem (2007) 0.81
Drug targeting strategies for photodynamic therapy. Anticancer Agents Med Chem (2012) 0.80
Covalent cell surface functionalization of human fetal osteoblasts for tissue engineering. Bioconjug Chem (2011) 0.80
Functionalized pyrrolidines inhibit alpha-mannosidase activity and growth of human glioblastoma and melanoma cells. J Med Chem (2005) 0.80
Cell response to the exposure to chitosan-TPP//alginate nanogels. Biomacromolecules (2011) 0.80
Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. Carcinogenesis (2004) 0.80
Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials. Expert Opin Ther Targets (2009) 0.80
Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension (2002) 0.79
Oxidosqualene cyclase from Saccharomyces cerevisiae, Trypanosoma cruzi, Pneumocystis carinii and Arabidopsis thaliana expressed in yeast: a model for the development of novel antiparasitic agents. Bioorg Med Chem Lett (2008) 0.79
Evaluation of dipeptide-derivatives of 5-aminolevulinic acid as precursors for photosensitizers in photodynamic therapy. Bioorg Med Chem (2003) 0.79
Chitosan-based nanogels for selective delivery of photosensitizers to macrophages and improved retention in and therapy of articular joints. J Control Release (2010) 0.79
Interaction of cationic ultrasmall superparamagnetic iron oxide nanoparticles with human melanoma cells. Nanomedicine (Lond) (2010) 0.79
2-Phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1 (TGR5). ChemMedChem (2012) 0.79
Transfer of ultrasmall iron oxide nanoparticles from human brain-derived endothelial cells to human glioblastoma cells. ACS Appl Mater Interfaces (2013) 0.78
Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death. Dalton Trans (2012) 0.78
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem (2012) 0.78
Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat (2014) 0.78
Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRalpha and beta. Bioorg Med Chem Lett (2006) 0.77
Chemical functionalization of bioceramics to enhance endothelial cells adhesion for tissue engineering. J Med Chem (2012) 0.77
Cellular delivery of pyrenyl-arene ruthenium complexes by a water-soluble arene ruthenium metalla-cage. Dalton Trans (2012) 0.77
Convenient synthesis of heterobifunctional poly(ethylene glycol) suitable for the functionalization of iron oxide nanoparticles for biomedical applications. Bioorg Med Chem Lett (2013) 0.77
G protein-coupled receptor transmembrane binding pockets and their applications in GPCR research and drug discovery: a survey. Curr Top Med Chem (2011) 0.77
Stress reaction of kidney epithelial cells to inorganic solid-core nanoparticles. Cell Biol Toxicol (2012) 0.76
Sawhorse-type diruthenium tetracarbonyl complexes containing porphyrin-derived ligands as highly selective photosensitizers for female reproductive cancer cells. J Biol Inorg Chem (2009) 0.76
Evaluation of the interaction between TGF beta and nitric oxide in the mechanisms of progression of colon carcinoma. Clin Exp Metastasis (2005) 0.76
Functionalization of microstructured open-porous bioceramic scaffolds with human fetal bone cells. Bioconjug Chem (2012) 0.76
Determination of intracellular prolyl/glycyl proteases in intact living human cells and protoporphyrin IX production as a reporter system. Chem Biol (2005) 0.76
S-alkylthiolation of O6-methylguanine-DNA-methyltransferase (MGMT) to sensitize cancer cells to anticancer therapy. Expert Opin Ther Targets (2007) 0.76
Expression of dual angiogenic/neurogenic growth factors in human primary brain tumors. J Neurooncol (2011) 0.76
Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors. J Med Chem (2003) 0.76
Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy. J Biol Inorg Chem (2008) 0.76
Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. Bioorg Med Chem Lett (2010) 0.75
Suitability of human and mammalian cells of different origin for the assessment of genotoxicity of metal and polymeric engineered nanoparticles. Nanotoxicology (2015) 0.75
Structure-based design, synthesis, and in vitro evaluation of nonpeptidic neprilysin inhibitors. Chembiochem (2004) 0.75
Correction to Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis. J Med Chem (2017) 0.75
Functionalized glycomers as growth inhibitors and inducers of apoptosis in human glioblastoma cells. J Med Chem (2003) 0.75
Surface functionalization of alumina ceramic foams with organic ligands. ACS Appl Mater Interfaces (2012) 0.75
Glycoside esters of 5-aminolevulinic acid for photodynamic therapy of cancer. Bioconjug Chem (2008) 0.75
Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2). Org Biomol Chem (2016) 0.75
Synthesis of triazole-Tethered pyrrolidine libraries: novel ECE inhibitors. Bioorg Med Chem Lett (2002) 0.75
Surface modification of biomaterials for conjugation with human fetal osteoblasts. Chimia (Aarau) (2013) 0.75
Efficient photodynamic therapy of cancer using chemotherapeutic porphyrin-ruthenium metalla-cubes. Bioorg Med Chem Lett (2011) 0.75